S&P 500   4,279.84 (+1.39%)
DOW   33,656.30 (+1.80%)
QQQ   355.00 (+0.85%)
AAPL   180.39 (+0.17%)
MSFT   335.10 (+0.76%)
META   273.81 (+0.44%)
GOOGL   125.10 (+1.12%)
AMZN   125.61 (+2.31%)
TSLA   215.57 (+3.88%)
NVDA   398.42 (+0.18%)
NIO   7.73 (+2.52%)
BABA   85.26 (+2.72%)
AMD   120.26 (+0.66%)
T   15.00 (-5.12%)
F   12.47 (+2.97%)
MU   69.27 (+0.26%)
CGC   0.84 (+0.48%)
GE   105.55 (+0.84%)
DIS   90.52 (+2.18%)
AMC   4.55 (+0.00%)
PFE   38.54 (+1.37%)
PYPL   64.21 (+1.84%)
NFLX   402.65 (-0.12%)
S&P 500   4,279.84 (+1.39%)
DOW   33,656.30 (+1.80%)
QQQ   355.00 (+0.85%)
AAPL   180.39 (+0.17%)
MSFT   335.10 (+0.76%)
META   273.81 (+0.44%)
GOOGL   125.10 (+1.12%)
AMZN   125.61 (+2.31%)
TSLA   215.57 (+3.88%)
NVDA   398.42 (+0.18%)
NIO   7.73 (+2.52%)
BABA   85.26 (+2.72%)
AMD   120.26 (+0.66%)
T   15.00 (-5.12%)
F   12.47 (+2.97%)
MU   69.27 (+0.26%)
CGC   0.84 (+0.48%)
GE   105.55 (+0.84%)
DIS   90.52 (+2.18%)
AMC   4.55 (+0.00%)
PFE   38.54 (+1.37%)
PYPL   64.21 (+1.84%)
NFLX   402.65 (-0.12%)
S&P 500   4,279.84 (+1.39%)
DOW   33,656.30 (+1.80%)
QQQ   355.00 (+0.85%)
AAPL   180.39 (+0.17%)
MSFT   335.10 (+0.76%)
META   273.81 (+0.44%)
GOOGL   125.10 (+1.12%)
AMZN   125.61 (+2.31%)
TSLA   215.57 (+3.88%)
NVDA   398.42 (+0.18%)
NIO   7.73 (+2.52%)
BABA   85.26 (+2.72%)
AMD   120.26 (+0.66%)
T   15.00 (-5.12%)
F   12.47 (+2.97%)
MU   69.27 (+0.26%)
CGC   0.84 (+0.48%)
GE   105.55 (+0.84%)
DIS   90.52 (+2.18%)
AMC   4.55 (+0.00%)
PFE   38.54 (+1.37%)
PYPL   64.21 (+1.84%)
NFLX   402.65 (-0.12%)
S&P 500   4,279.84 (+1.39%)
DOW   33,656.30 (+1.80%)
QQQ   355.00 (+0.85%)
AAPL   180.39 (+0.17%)
MSFT   335.10 (+0.76%)
META   273.81 (+0.44%)
GOOGL   125.10 (+1.12%)
AMZN   125.61 (+2.31%)
TSLA   215.57 (+3.88%)
NVDA   398.42 (+0.18%)
NIO   7.73 (+2.52%)
BABA   85.26 (+2.72%)
AMD   120.26 (+0.66%)
T   15.00 (-5.12%)
F   12.47 (+2.97%)
MU   69.27 (+0.26%)
CGC   0.84 (+0.48%)
GE   105.55 (+0.84%)
DIS   90.52 (+2.18%)
AMC   4.55 (+0.00%)
PFE   38.54 (+1.37%)
PYPL   64.21 (+1.84%)
NFLX   402.65 (-0.12%)
NYSE:TMO

Thermo Fisher Scientific (TMO) Competitors

$522.90
+3.52 (+0.68%)
(As of 11:16 AM ET)
Compare
Today's Range
$520.16
$527.16
50-Day Range
$508.46
$591.13
52-Week Range
$475.77
$611.06
Volume
564,116 shs
Average Volume
1.45 million shs
Market Capitalization
$201.69 billion
P/E Ratio
34.09
Dividend Yield
0.27%
Price Target
$631.31

TMO vs. NVS, PFE, ABT, AZN, ABBV, BMY, SNY, MRK, AMGN, and MDT

Should you be buying Thermo Fisher Scientific stock or one of its competitors? The main competitors of Thermo Fisher Scientific include Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), AstraZeneca (AZN), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Sanofi (SNY), Merck & Co., Inc. (MRK), Amgen (AMGN), and Medtronic (MDT). These companies are all part of the "medical" sector.

Thermo Fisher Scientific vs.

Thermo Fisher Scientific (NYSE:TMO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Thermo Fisher Scientific received 502 more outperform votes than Novartis when rated by MarketBeat users. Likewise, 81.91% of users gave Thermo Fisher Scientific an outperform vote while only 61.51% of users gave Novartis an outperform vote.

CompanyUnderperformOutperform
Thermo Fisher ScientificOutperform Votes
1023
81.91%
Underperform Votes
226
18.09%
NovartisOutperform Votes
521
61.51%
Underperform Votes
326
38.49%

85.9% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 8.1% of Novartis shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Thermo Fisher Scientific has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

Novartis has a net margin of 13.78% compared to Thermo Fisher Scientific's net margin of 13.75%. Novartis' return on equity of 23.29% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific 13.75% 19.16% 8.85%
Novartis 13.78% 23.29% 11.64%

In the previous week, Thermo Fisher Scientific had 3 more articles in the media than Novartis. MarketBeat recorded 15 mentions for Thermo Fisher Scientific and 12 mentions for Novartis. Novartis' average media sentiment score of 0.70 beat Thermo Fisher Scientific's score of 0.00 indicating that Novartis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Thermo Fisher Scientific
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Novartis
7 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Thermo Fisher Scientific currently has a consensus price target of $631.31, suggesting a potential upside of 21.55%. Novartis has a consensus price target of $82.25, suggesting a potential downside of 15.30%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, equities research analysts clearly believe Thermo Fisher Scientific is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67
Novartis
2 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.09

Thermo Fisher Scientific pays an annual dividend of $1.40 per share and has a dividend yield of 0.3%. Novartis pays an annual dividend of $2.27 per share and has a dividend yield of 2.3%. Thermo Fisher Scientific pays out 9.1% of its earnings in the form of a dividend. Novartis pays out 69.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has higher revenue and earnings than Thermo Fisher Scientific. Novartis is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$44.92 billion4.46$6.95 billion$15.3433.86
Novartis$50.55 billion4.07$6.96 billion$3.2529.88

Summary

Thermo Fisher Scientific beats Novartis on 13 of the 20 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMO vs. The Competition

MetricThermo Fisher ScientificMeasuring & controlling devices IndustryMedical SectorNYSE Exchange
Market Cap$196.12B$17.83B$4.51B$14.52B
Dividend Yield0.28%8.79%2.42%4.12%
P/E Ratio33.868.1686.2816.98
Price / Sales4.463.823,548.218.96
Price / Cash15.9031.7190.2823.01
Price / Book4.734.055.149.15
Net Income$6.95B$568.69M$117.85M$900.50M
7 Day Performance-0.51%-2.90%2.09%0.01%
1 Month Performance-4.49%1.77%4.61%0.16%
1 Year Performance-8.90%-10.30%21.42%-10.66%

Thermo Fisher Scientific Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVS
Novartis
2.0277 of 5 stars
$96.55
-1.3%
$82.25
-14.8%
+8.3%$204.65B$50.55B29.71101,703News Coverage
PFE
Pfizer
3.0419 of 5 stars
$37.02
-1.5%
$47.33
+27.9%
-27.4%$208.99B$100.33B7.2983,000
ABT
Abbott Laboratories
3.0159 of 5 stars
$101.72
-1.1%
$121.26
+19.2%
-10.7%$176.89B$43.65B30.92115,000Analyst Downgrade
AZN
AstraZeneca
2.4922 of 5 stars
$71.43
-1.5%
$103.00
+44.2%
+10.2%$221.41B$44.35B46.9983,500
ABBV
AbbVie
2.7795 of 5 stars
$136.48
-0.8%
$163.40
+19.7%
-8.6%$240.79B$58.05B32.2650,000Options Volume
BMY
Bristol-Myers Squibb
2.4857 of 5 stars
$63.70
-0.2%
$79.43
+24.7%
-13.7%$133.82B$46.16B18.5734,300Analyst Revision
SNY
Sanofi
2.4601 of 5 stars
$50.45
-3.9%
$94.50
+87.3%
-5.2%$127.23B$45.31B18.0891,573Dividend Cut
Ex-Dividend
MRK
Merck & Co., Inc.
2.9017 of 5 stars
$109.18
-1.7%
$120.75
+10.6%
+21.7%$277.04B$59.28B21.3269,000
AMGN
Amgen
2.6919 of 5 stars
$218.53
+0.7%
$250.94
+14.8%
-15.4%$116.77B$26.32B14.8625,200Analyst Downgrade
MDT
Medtronic
2.7812 of 5 stars
$82.51
+1.3%
$91.37
+10.7%
-15.4%$109.77B$31.23B29.2695,000Analyst Upgrade

Related Companies and Tools

This page (NYSE:TMO) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -